Artia Global Partners
Latest statistics and disclosures from Artia Global Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NVO, LLY, MRK, Cytokinetics, Cytokinetics, and represent 67.42% of Artia Global Partners's stock portfolio.
- Added to shares of these 10 stocks: LLY (+$39M), Cytokinetics (+$34M), Cytokinetics (+$33M), Lilly Eli & Co option (+$23M), NVO, CYTK, VRNA, INSM, OCUL, EYPT.
- Started 12 new stock positions in Cytokinetics, IMVT, CYTK, EYPT, INSM, Lilly Eli & Co option, Structure Therapeutics, RAPT, Cytokinetics, VRNA. OCUL, APGE.
- Reduced shares in these 10 stocks: Seagen (-$11M), ROIV (-$11M), ETNB (-$7.2M), SRPT (-$6.9M), , ARGX (-$5.7M), BMRN, , TMO, Cymabay Therapeutics.
- Sold out of its positions in ALNY, Cymabay Therapeutics, ETNB, SRPT, Seagen, TMO, VRTX, ROIV.
- Artia Global Partners was a net buyer of stock by $89M.
- Artia Global Partners has $344M in assets under management (AUM), dropping by 42.89%.
- Central Index Key (CIK): 0001937964
Tip: Access up to 7 years of quarterly data
Positions held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 31 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Novo-nordisk A S Adr (NVO) | 21.7 | $75M | +5% | 722k | 103.45 |
|
| Eli Lilly & Co. (LLY) | 15.7 | $54M | +253% | 93k | 582.92 |
|
| Merck & Co (MRK) | 10.4 | $36M | 329k | 109.02 |
|
|
| Cytokinetics Call Call Option | 9.8 | $34M | NEW | 405k | 83.49 |
|
| Cytokinetics Put Put Option | 9.7 | $33M | NEW | 401k | 83.49 |
|
| Eli Lilly & Co Put Put Option | 6.8 | $23M | NEW | 40k | 582.92 |
|
| Abbvie (ABBV) | 4.1 | $14M | 91k | 154.97 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 3.8 | $13M | -30% | 34k | 380.43 |
|
| Astrazeneca Sponsored Adr (AZN) | 3.7 | $13M | 191k | 67.35 |
|
|
| Viking Therapeutics (VKTX) | 2.1 | $7.1M | 384k | 18.61 |
|
|
| Axsome Therapeutics (AXSM) | 2.0 | $7.0M | 88k | 79.59 |
|
|
| Neurocrine Biosciences (NBIX) | 1.7 | $5.9M | 45k | 131.76 |
|
|
| Intra Cellular Therapies (ITCI) | 0.9 | $3.0M | 42k | 71.62 |
|
|
| BioMarin Pharmaceutical (BMRN) | 0.8 | $2.8M | -63% | 29k | 96.42 |
|
| Cytokinetics Com New (CYTK) | 0.8 | $2.7M | NEW | 32k | 83.49 |
|
| Verona Pharma Sponsored Ads (VRNA) | 0.8 | $2.6M | NEW | 131k | 19.88 |
|
| Protagonist Therapeutics (PTGX) | 0.7 | $2.6M | 112k | 22.93 |
|
|
| Vaxcyte (PCVX) | 0.7 | $2.4M | 39k | 62.80 |
|
|
| Insmed Com Par $.01 (INSM) | 0.7 | $2.3M | NEW | 75k | 30.99 |
|
| Ocular Therapeutix (OCUL) | 0.6 | $2.0M | NEW | 440k | 4.46 |
|
| Pliant Therapeutics (PLRX) | 0.5 | $1.8M | 100k | 18.11 |
|
|
| Charles River Laboratories (CRL) | 0.5 | $1.6M | 6.9k | 236.40 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.3 | $1.2M | NEW | 50k | 23.11 |
|
| Waters Corporation (WAT) | 0.3 | $937k | 2.8k | 329.23 |
|
|
| Immunovant (IMVT) | 0.3 | $902k | NEW | 21k | 42.13 |
|
| Rapt Therapeutics (RAPT) | 0.1 | $488k | NEW | 20k | 24.85 |
|
| Structure Therapeutics Put Put Option | 0.1 | $408k | NEW | 10k | 40.76 |
|
| Biomea Fusion (BMEA) | 0.1 | $370k | 26k | 14.52 |
|
|
| Apogee Therapeutics (APGE) | 0.1 | $290k | NEW | 10k | 27.94 |
|
| Gritstone Oncology Ord (GRTS) | 0.1 | $194k | 95k | 2.04 |
|
|
| Tyra Biosciences (TYRA) | 0.0 | $142k | -77% | 10k | 13.85 |
|
Past Filings by Artia Global Partners
SEC 13F filings are viewable for Artia Global Partners going back to 2022
- Artia Global Partners 2023 Q4 filed Feb. 14, 2024
- Artia Global Partners 2023 Q3 filed Nov. 14, 2023
- Artia Global Partners 2023 Q2 filed Aug. 14, 2023
- Artia Global Partners 2023 Q1 filed May 15, 2023
- Artia Global Partners 2022 Q4 filed Feb. 14, 2023